Results 241 to 250 of about 201,064 (349)

Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death. [PDF]

Cell Commun Signal
Qiu Y, Liu Y, Ding H, Xin W, Lu S, Hu Y, Chen J, Weng Q, Wang J, Fang L.   +9 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Late hepatotoxicity after treatment for childhood cancer. [PDF]

World J Hepatol
Roganovic J, Vidovic A, Dordevic A.
europepmc   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

Evaluation of Latent Tuberculosis Infection Risk in Liver Transplant Recipients. [PDF]

J Clin Med
Öz Kahya M, Erol S, Kış Gökçecik D, Kırımker EO, Çınar G, Kocaay AF, Balcı D, Özdemir Kumbasar Ö.   +7 more
europepmc   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

A scoping review of interventions to prevent and treat adverse events during treatment of rifampin-susceptible tuberculosis. [PDF]

PLoS One
Burman WJ, Martins MF, Flynn D, Johnston J, Sinha P, Horsburgh CR.   +5 more
europepmc   +1 more source

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis. [PDF]

BMC Cancer
Wang Z, Meng J, Liu G, Wang Y, Li Y, Zhang C, Liu Y, Sun G.   +7 more
europepmc   +1 more source